美华盛顿州检察官入禀控告强生 促就止痛药滥用风波赔偿
美国华盛顿州检察官入禀金郡(King County)最高法院,检控强生(Johnson & Johnson)在推广止痛药时虚假宣传不会导致上瘾,违反该州消费者保障法例,寻求民事惩罚及赔偿。强生被指向医药丛提供生产鸦片类止痛药的材料,单在华盛顿州,鸦片类药销售在1997年至2011年期间急逾5倍,高峰期每日有1.12亿剂量处方鸦片药被分发。
州检察官要求强生放弃有关生产於该州带来的利润,估计数额以百万美元计。被告人为强生旗下分支Janssen Pharmaceutical Inc.。
奥克拉荷马州州法官去年11月指令强生就鸦片药被滥用风波,向奥克拉荷马州赔偿4.65亿美元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.